Get the Stockscreener App
3.15
5.26%
-0.175
After Hours:
3.15
Polypid Ltd stock is traded at $3.15, with a volume of 377.85K.
It is down -5.26% in the last 24 hours and down -8.70% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$3.325
Open:
$3.28
24h Volume:
377.85K
Relative Volume:
4.81
Market Cap:
$50.08M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.1601
EPS:
-19.67
Net Cash Flow:
$-47.63M
1W Performance:
-10.00%
1M Performance:
-8.70%
6M Performance:
+28.57%
1Y Performance:
-10.26%
1-Day Range:
$3.06
$3.405
1-Week Range:
$3.06
$3.56
52-Week Range:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.15 | 52.86M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
How to use a screener to detect PolyPid Ltd. breakoutsJuly 2025 Drop Watch & Community Shared Stock Ideas - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for PolyPid (NASDAQ:PYPD) - MarketBeat
Analyzing recovery setups for PolyPid Ltd. investors2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
Is this a good reentry point in PolyPid Ltd.2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
Best data tools to analyze PolyPid Ltd. stockMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Increase in Short Interest - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - MarketBeat
Price action breakdown for PolyPid Ltd.July 2025 Spike Watch & Long-Term Investment Growth Plans - newser.com
Will PolyPid Ltd. see short term momentumBuy Signal & Stock Portfolio Risk Management - newser.com
Tools to monitor PolyPid Ltd. recovery probabilityBreakout Watch & Safe Capital Investment Plans - newser.com
Is PolyPid Ltd a good long term investmentMid Cap Growth Trends & Achieve Consistent Profits - earlytimes.in
PolyPid to present phase 3 SHIELD II trial results at ACS congress - Investing.com Nigeria
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 By Investing.com - Investing.com Australia
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 - Investing.com India
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress - The Manila Times
PolyPid Ltd. Announces Presentation of Phase 3 SHIELD II Trial Results at 2025 ACS Clinical Congress - Quiver Quantitative
PolyPid to Present Its Positive Phase 3 SHIELD II Topline - GlobeNewswire
PolyPid (NASDAQ:PYPD) & Cronos Group (NASDAQ:CRON) Head to Head Survey - Defense World
What analysts say about PolyPid Ltd stockVolume Analysis Techniques & Invest Smarter With Data-Driven Models - earlytimes.in
What drives PolyPid Ltd stock priceFibonacci Retracement Levels & Free Rapid Growing Investment Returns - earlytimes.in
PolyPid Ltd. (NASDAQ:PYPD) Receives $12.40 Consensus PT from Analysts - Defense World
PolyPid (NASDAQ:PYPD) Rating Increased to Hold at Wall Street Zen - MarketBeat
What to expect from PolyPid Ltd. in the next 30 days2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9%Time to Buy? - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9% – Time to Buy? - Defense World
Will a bounce in PolyPid Ltd. offer an exitBuy Signal & Free Daily Entry Point Trade Alerts - newser.com
Multi factor analysis applied to PolyPid Ltd.Exit Point & Verified High Yield Trade Plans - newser.com
Real time breakdown of PolyPid Ltd. stock performanceMarket Rally & AI Driven Price Predictions - newser.com
Does PolyPid Ltd. show high probability of reboundExit Point & Safe Entry Trade Signal Reports - newser.com
Strategies to average down on PolyPid Ltd.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
PolyPid completes Israeli Ministry of Health GMP inspection - MSN
PolyPid Appoints New Chief Medical Officer Amid Strategic Advancements - msn.com
Is PolyPid Ltd. forming a reversal patternRisk Management & Weekly High Return Stock Opportunities - newser.com
Decliners Report: Can PolyPid Ltd. ride the EV waveWeekly Market Report & Entry Point Strategy Guides - خودرو بانک
Applying Wyckoff theory to PolyPid Ltd. stockMarket Risk Summary & Proven Capital Preservation Methods - newser.com
Profit Review: Is now the right time to enter ATIIWJuly 2025 Pullbacks & Comprehensive Market Scan Insights - khodrobank.com
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):